PUT - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 18:44:55 27/06/2024 BST | ||
| 3.78 EUR | -2.07% |
|
| Current month | -35.71% | ||
| 1 month | -23.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 3.78 | -2.07% |
| 26/06/24 | 3.86 | -3.50% |
| 25/06/24 | 4 | +8.11% |
| 24/06/24 | 3.7 | -15.72% |
| 21/06/24 | 4.39 | +8.13% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 06:44 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM75SD |
| ISIN | DE000VM75SD4 |
| Date issued | 08/01/2024 |
| Strike | 512.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.44 € |
|---|---|
| Lowest since issue | 2.53 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
